 Edesa Biotech Inc NASDAQ: EDSA issued an update for the Phase 23 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for hospitalized COVID-19 patients. Edesa reported that more than 525 subjects had been randomized into the study. 